Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico | npj Vaccines – Nature.com

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico | npj Vaccines  Nature.com

Read the original here:

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico | npj Vaccines - Nature.com

Related Posts
Tags: